Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Fiche publication

Date publication

mars 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BERTAUT Aurélie , Dr COUDERT Bruno , Pr COUTANT Charles , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr HENNEQUIN Audrey , Dr JOUANNAUD Christelle , Dr MAYEUR Didier

Tous les auteurs :
Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Jacinto S, Michel E, Amet A, Coutant C, Costa B, Jouannaud C, Deblock M, Levy C, Ferrero JM, Kerbrat P, Brain E, Mouret-Reynier MA, Coudert B, Bertaut A, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38554542

Résumé

The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.